Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.

• DOI: 10.1200/jco.2023.41.6_suppl.185
• Publication Date: 2023-03-14T15:22:32Z
• Authors: Can Aydogdu; Florian Urban; Alexander Tamalunas; Elena Berg; Melanie Götz; Severin Rodler; Volker Heinemann; Christian Stief; Jozefina Casuscelli

185 Background: Several phase III trials have assessed efficacy and safety of 6 cycles docetaxel combined to androgen deprivation therapy (ADT). This is the current standard care for a subgroup patients. We aimed assess whether treatment beyond prove be more effective than care. Methods: retrospectively analyzed patients with histologically confirmed adenocarcinoma prostate radiologically proven metastatic disease from large tertiary center. All mHSPC were treated in first line ADT combination (75 mg/m 2 ) (D-ADT) intravenously on day each 21-day cycle. A subset was cycles. Clinical pathological variables analyzed, progression free survival D-ADT (PFS1), subsequent (PFS2) overall (OS) endpoints by log- rank test. Results: Between 2018-2022 total 74 followed-up median time 13.7 months. Mean age 66.2 years (range 50.1-82.4), 79.7% had GS≥8, 73% CHAARTED high-volume 76% LATITUDE high risk disease. 43 pts. ≤ (D-ADTstand) (2.4 % 1-2 cycles; 97.6 ≥3 mean 5.3 cycles) 31 >6 (D-ADTadd) (25.8 7-8 74.2% ≥9-10 cycles, 9.2 cycles). No significant differences observed PFS1 (12.4 vs. mos.) PFS2 (5.4 9.6 mos.). Median OS D-ADTstand group 39.8 mos., D-ADTadd not yet reached. Conclusions: While proved feasible without additional toxicity, superior compared Overall data mature yet, but benefit chemotherapy upfront debatable leverages further studies light upcoming triplet combinations mHSPC, that presumably will render obsolete future. [Table: see text]